Loading...
XSHE
300015
Market cap12bUSD
Jul 22, Last price  
8.89CNY
1D
1.25%
1Q
-14.60%
Jan 2017
-33.11%
IPO
-30.92%
Name

Aier Eye Hospital Group Co Ltd

Chart & performance

D1W1MN
XSHE:300015 chart
P/E
25.51
P/S
3.70
EPS
0.35
Div yield, %
1.80%
Shrs. gr., 5y
0.76%
Rev. gr., 5y
13.41%
Revenues
22.35b
+6.53%
191,188,834314,903,815425,261,075599,343,186864,877,4501,310,624,4721,640,130,4501,984,967,2872,402,047,6163,165,580,4714,000,401,6705,962,845,5598,008,573,9539,990,103,97511,912,409,98415,000,809,43716,109,946,68620,367,156,73820,982,894,14822,352,604,724
Net income
3.24b
-8.88%
14,591,52138,979,51661,366,55592,489,402120,309,791171,927,760182,546,816223,495,561309,186,285428,043,987556,990,793742,514,5421,008,937,3531,378,920,9781,723,805,3422,323,343,9632,524,230,8483,358,871,5393,556,055,8383,240,259,465
CFO
5.97b
+22.35%
36,904,48992,187,299121,174,149169,137,874239,966,170257,108,449301,818,986412,651,458453,683,706522,168,231675,098,1661,330,404,5121,399,870,3982,078,432,7343,343,611,3254,084,103,9584,490,674,8115,871,890,0914,881,686,2015,972,727,509
Dividend
Jul 17, 20260.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aier Eye Hospital Group Co., Ltd. is a prominent provider of ophthalmic healthcare services and institutions. Its comprehensive medical offerings encompass specialties such as the diagnosis and treatment of fundus diseases, optometry, refractive correction, glaucoma, corneal conditions, and cataracts. Beyond direct patient care, the company also conducts training courses focused on cataract prevention and management. The group boasts an extensive international footprint, operating approximately 500 ophthalmic facilities across mainland China, with additional presences including 86 in Europe, 1 in the United States, 7 in Hong Kong, and 12 throughout Southeast Asia. Founded in 2007, Aier Eye Hospital Group maintains its headquarters in Changsha, China.
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT